Gritstone Oncology, Inc. Banner Image

Gritstone Oncology, Inc.

  • Ticker GRTS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Gritstone Oncology, Inc. Logo Image
  • 51-200 Employees
  • Based in Emeryville, California
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigensMore (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization.
4.8 / 5.0 (180)

Gritstone Oncology, Inc. reports have an aggregate usefulness score of 4.8 based on 180 reviews.

Gritstone Oncology, Inc.

Most Recent Annual Report

Gritstone Oncology, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Gritstone Oncology, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!